Tag: FL

Poster-Disease-modifying Therapy

Number-Needed-to-Treat (NNT) to Prevent One Relapse in Recent Teriflunomide-Controlled Clinical Trials in Relapsing MS

Background: Over the past two and a half decades, there has been an exponential increase in FDA approvals of treatments for relapsing forms...

Read More

Poster-Disease-modifying Therapy

Number-Needed-to-Harm (NNH) in Alemtuzumab and Ocrelizumab Pivotal Clinical Trials in Relapsing MS

Background: Alemtuzumab (ALE) and ocrelizumab (OCR) are widely recognized as among the highest efficacy multiple sclerosis (MS) disease...

Read More

Poster-Complementary and Alternative Therapies

Evaluation of a 6 Week Integrative Medicine Workshop Series on Quality of Life, Self-Efficacy and Wellness in MS

Background: MS care provided in a comprehensive MS center improves outcomes. Well-established MS centers struggle to include complementary...

Read More

Platform-Disease Modifying Therapies

Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials

Background: Ublituximab, a novel monoclonal antibody, targets a unique epitope on the CD20 antigen and is glycoengineered for enhanced...

Read More

Platform-Disease Management

Optical Coherence Tomography As a Biomarker for Multiple Sclerosis Studies

Background: Optic Neuritis occurs in about 20% of MS patients as the initial symptom. Objectives: To assess the clinical utility of optical...

Read More